Groundbreaking discoveries have shed light on the mechanisms underlying three distinct subtypes of mismatch repair deficient high-grade gliomas, a pivotal development in understanding these aggressive brain tumors. These findings not only enhance our comprehension of tumor formation but also elucidate the varied responses patients exhibit to immunotherapy, paving the way for more tailored treatment strategies.
High-grade gliomas represent a category of particularly lethal brain tumors, especially prevalent among children and young adults. In certain pediatric cases, these tumors arise due to a deficiency in mismatch repair (MMRD), a condition marked by hypermutation—where an excessive number of mutations accumulate rapidly within tumor cells—and a notable resistance to traditional treatment modalities like chemotherapy and radiation therapy.
The tumors associated with this deficiency are classified as primary mismatch repair deficient high-grade gliomas (priMMRD-HGG). Due to their extensive mutation profiles, there has been a paradigm shift towards using immunotherapy, which harnesses the body's immune system to combat cancer by specifically targeting malignant cells.
Although immunotherapy has resulted in improved survival outcomes, healthcare providers have observed three different patterns of patient response, alongside variations in imaging results and age at diagnosis.
A study published in Nature Genetics, led by Dr. Uri Tabori along with his colleagues Drs. Anirban Das and Cynthia Hawkins at The Hospital for Sick Children (SickKids), focuses on analyzing genomic and clinical data from priMMRD-HGG to gain deeper insights into these discrepancies in treatment response.
This research identifies three unique molecular pathways that correspond with clinical observations, thereby forming a foundation for developing more precise therapies. It also raises hopes for potential advancements in vaccine development aimed at these tumor types.
Nicholas Fernandez, the lead author and a Research Fellow in the Tabori Lab, emphasizes the significance of these rare mismatch repair deficient gliomas, stating, "This rare population of mismatch repair deficient gliomas offers unique insight into how genome instability drives all gliomas and is already leading to new treatment strategies and clinical trials for patients."
The study categorized 162 priMMRD-HGG tumors from 152 patients into three subgroups using a distinctive global cohort from the International Replication Repair Deficiency Consortium:
priMMRD-1: The Ultra Hypermutant - Representing 62 percent of the analyzed tumors, this subgroup exhibits both MMRD mutations and polymerase proofreading deficiency (PPD), making them highly responsive to immunotherapy. A pioneering clinical trial called U-R-Immune Glioma, spearheaded by Drs. Eric Bouffet and Das at SickKids, is exploring an immunotherapy-first strategy for these patients, eliminating the need for initial radiation therapy.
priMMRD-2: The Double Agent - Comprising 19 percent of the gliomas investigated, these tumors present MMRD mutations without PPD or alterations in the IDH1 gene. For patients in this group, single-agent immunotherapy tends to be less effective; however, the addition of a second agent could enhance treatment outcomes. The OPTIMISE trial, directed by Dr. Daniel Morgenstern at SickKids, employs an adaptive trial design to focus on these specific genetic characteristics.
priMMRD-3: The Immune Cold - Accounting for the remaining 19 percent of the tumors studied, this subgroup contains MMRD mutations alongside variations in the IDH1 gene. Although their response to monotherapy is often inadequate, researchers and clinicians at SickKids are actively working on a clinical trial that combines targeted immunotherapies with an IDH1 inhibitor, aiming to offer more personalized care for these patients.
The implications of these findings extend beyond immediate patient care. The research team has proposed that the World Health Organization (WHO) reclassify priMMRD-3 as a subtype of astrocytoma, while designating priMMRD-1 and priMMRD-2 as specific types of pediatric high-grade gliomas. Such reclassification would more accurately reflect their molecular and clinical behaviors, potentially accelerating future research initiatives and collaborations with scientists globally focused on these exceptionally rare tumor subtypes.
One exciting avenue currently being explored is the development of a vaccine aimed at intercepting cancer cells earlier in their progression through a strategy known as immune interception. Dr. Tabori, who leads neuro-oncology at SickKids, articulates the promising nature of this research, stating, "These tumors have some of the highest mutations in humans, but this study revealed that these mutations are not random. This means the tumors share mutations that can be intercepted earlier to prevent their progression with approaches such as vaccines. In the lab, we're already looking for ways to target and destroy cancer cells before they spread and become deadly."
While still in its nascent stages, the research team is optimistic that a more nuanced understanding of these tumor subtypes will facilitate increasingly proactive and tailored treatments for each child's unique tumor profile. This effort is part of a broader initiative known as the immune cancer interception program, led by Drs. Peter Dirks, James Rutka, Hawkins, and Tabori at the Brain Tumour Research Centre at SickKids.
This significant study received funding from the Canadian Institutes of Health Research (CIHR), the Terry Fox Research Institute, and Stand Up to Cancer.
